SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 29.31 CNY | -1.11% |
|
-2.69% | +12.82% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 8,632 | 8,620 | 8,527 | 9,495 | 13,469 | 15,172 |
| Enterprise Value (EV) 1 | 7,356 | 7,375 | 6,889 | 7,446 | 10,057 | 11,597 |
| P/E ratio | 15.4 x | 15.2 x | 14.7 x | 13.6 x | 15.7 x | 13.5 x |
| Yield | 6.77% | 6.78% | 2.39% | 4.25% | 4.31% | 5.77% |
| Capitalization / Revenue | 1.93 x | 1.97 x | 2.46 x | 2.13 x | 2.64 x | 2.66 x |
| EV / Revenue | 1.64 x | 1.69 x | 1.99 x | 1.67 x | 1.97 x | 2.03 x |
| EV / EBITDA | 9.45 x | 8.7 x | 8.52 x | 7.97 x | 7.84 x | 8.55 x |
| EV / FCF | 25.4 x | 23.2 x | 10.1 x | 10.5 x | 6.48 x | 31 x |
| FCF Yield | 3.94% | 4.31% | 9.88% | 9.52% | 15.4% | 3.22% |
| Price to Book | 2.64 x | 2.67 x | 2.66 x | 2.61 x | 3.22 x | 3.19 x |
| Nbr of stocks (in thousands) | 584,000 | 584,000 | 581,265 | 576,870 | 581,050 | 584,000 |
| Reference price 2 | 14.78 | 14.76 | 14.67 | 16.46 | 23.18 | 25.98 |
| Announcement Date | 3/20/19 | 4/27/20 | 4/20/21 | 4/21/22 | 4/11/23 | 4/25/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 4,472 | 4,371 | 3,462 | 4,461 | 5,095 | 5,700 |
| EBITDA 1 | 778.5 | 847.9 | 809 | 933.8 | 1,283 | 1,356 |
| EBIT 1 | 635.7 | 702.2 | 661.9 | 771.3 | 1,022 | 1,184 |
| Operating Margin | 14.21% | 16.06% | 19.12% | 17.29% | 20.07% | 20.76% |
| Earnings before Tax (EBT) 1 | 720.4 | 778 | 766.8 | 894.5 | 1,081 | 1,355 |
| Net income 1 | 563.3 | 565.4 | 584.5 | 704.7 | 867.2 | 1,119 |
| Net margin | 12.6% | 12.93% | 16.88% | 15.8% | 17.02% | 19.63% |
| EPS 2 | 0.9600 | 0.9700 | 1.000 | 1.210 | 1.480 | 1.920 |
| Free Cash Flow 1 | 289.7 | 317.9 | 681 | 708.5 | 1,552 | 373.9 |
| FCF margin | 6.48% | 7.27% | 19.67% | 15.88% | 30.47% | 6.56% |
| FCF Conversion (EBITDA) | 37.21% | 37.49% | 84.17% | 75.88% | 121.02% | 27.57% |
| FCF Conversion (Net income) | 51.42% | 56.23% | 116.51% | 100.54% | 179.02% | 33.41% |
| Dividend per Share 2 | 1.000 | 1.000 | 0.3500 | 0.7000 | 1.000 | 1.500 |
| Announcement Date | 3/20/19 | 4/27/20 | 4/20/21 | 4/21/22 | 4/11/23 | 4/25/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - |
| Net Cash position 1 | 1,276 | 1,244 | 1,638 | 2,049 | 3,411 | 3,576 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - |
| Free Cash Flow 1 | 290 | 318 | 681 | 709 | 1,552 | 374 |
| ROE (net income / shareholders' equity) | 18.4% | 18.5% | 18.2% | 20.8% | 21.7% | 24.7% |
| ROA (Net income/ Total Assets) | 8.34% | 8.47% | 7.94% | 8.97% | 10.1% | 10.6% |
| Assets 1 | 6,755 | 6,679 | 7,362 | 7,857 | 8,595 | 10,526 |
| Book Value Per Share 2 | 5.600 | 5.540 | 5.510 | 6.310 | 7.200 | 8.160 |
| Cash Flow per Share 2 | 2.100 | 2.520 | 2.860 | 2.250 | 4.110 | 3.920 |
| Capex 1 | 321 | 374 | 213 | 118 | 153 | 149 |
| Capex / Sales | 7.18% | 8.56% | 6.14% | 2.65% | 3% | 2.62% |
| Announcement Date | 3/20/19 | 4/27/20 | 4/20/21 | 4/21/22 | 4/11/23 | 4/25/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +12.82% | 2.39B | |
| +22.35% | 44.12B | |
| +22.22% | 22.61B | |
| +17.81% | 15.11B | |
| +15.73% | 13.61B | |
| +57.91% | 13.34B | |
| -8.98% | 6.94B | |
| -0.05% | 6.79B | |
| +15.65% | 5.75B | |
| -8.87% | 5.73B |
- Stock Market
- Equities
- 002737 Stock
- Financials Sunflower Pharmaceutical Group Co.,Ltd
